Lesson plan
Imagabalin
Imagabalin ( , ; developmental code name PD-0332334) was an investigational drug that acts as a ligand for the α 2 δ subunit of the voltage-dependent calcium channel, with some selectivity for the α 2 δ 1 subunit over α 2 δ 2 . It was under development by Pfizer as a pharmaceutical medication due to its hypothesized anxiolytic, analgesic, hypnotic, and anticonvulsant-like activity. It reached phase-III clinical trials for treatment of generalized anxiety disorder; however, the trials were terminated by the manufacturer. The drug is no longer under development.
Article summary
Imagabalin ( , ; developmental code name PD-0332334) was an investigational drug that acts as a ligand for the α 2 δ subunit of the voltage-dependent calcium channel, with some selectivity for the α 2 δ 1 subunit over α 2 δ 2 . It was under development by Pfizer as a pharmaceutical medication due to its hypothesized anxiolytic, analgesic, hypnotic, and anticonvulsant-like activity. It reached phase-III clinical trials for treatment of generalized anxiety disorder; however, the trials were terminated by the manufacturer. The drug is no longer under development.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.